Abstract:There is no consensus for the treatment of recurrent rectal cancer. As FOLFOX has been the standard adjuvant chemotherapy, most recurrent patients have received oxaliplatin previously. This study is to investigate the local effect and toxicity of irinotecan and capecitabine concurrent with intensity-modulated radiation therapy in the treatment of recurrent rectal cancer. Fifty-eight patients (median age 53 years; m/f: 37:21) diagnosed with recurrent rectal cancer were treated in our hospital from October 2009 to November 2011. Eighty-two recurrent sites in all patients were included in which there were 27 cases with single site and 31 cases with multiple ones. Thirty-nine patients were confirmed recurrent rectal cancer without extra pelvic metastases while 19 patients with extra pelvic metastases. All patients underwent pelvic intensity-modulated radiation therapy of 45 Gy (1.8 Gy per fraction) followed by a boost of 10 Gy to 16 Gy (2 Gy per fraction) to the recurrent tumors. The concurrent chemotherapy regimen was irinotecan 50 mg/m2, weekly and capecitabine 625 mg/m2, bid (Mon-Fri.). Radical surgery was recommended if patients without extra pelvic metastases and the recurrent lesions were evaluated as resectable. The patients were follow-up every 3 months with clinical examinations, abdominal and pelvic CTs or MRIs. Tumor response was evaluated using CT/MRIs according to the RECIST criteria or postoperative pathological findings. NCI-CTC 3.0 was used to score the toxicities. The entire cohort included 82 recurrent sites, for the location of them, 30 sites were in peri-rectal region, 22 in pre-sacral region, 4 at external iliac nodal region, and 3 at inguinal nodal region. Eleven patients with locally recurrent rectal cancer underwent radical resections (R0) post chemoradiation. The pathologic complete response was observed in 7 of 11 patients. Clinical complete response was observed in 1 patient (1.7%) and partial response was 19 patients (32.8%). Only 4 patients showed progressive disease during or shortly after treatment. Of 41 symptomatic patients, clinical complete and partial symptom reliefs with chemoradiation were achieved in 56.1% and 36.6%. Only 2 patients experienced grade 4 leukopenia. The more common grade 3 toxicities were diarrhea (14 patients). In addition, grade 3 radiation dermatitis, leukopenia, and cystitis were observed in 5, 4, and 2 patients, respectively. This study showed irinotecan and capecitabine concurrent with intensity-modulated radiation therapy can relieved local symptoms significantly and exhibited promising efficacy with manageable toxicities in the recurrent rectal cancer. To improve the R0 resectable rate will be investigated in further study.

Three Dimensional-Conformal Radiation Therapy Combined with Chemotherapy for Locally Advanced and Recurrent Rectal Cancer

Study of Late Course Three Dimensional-Conformal Radiotherapy Combined with Chemotherapy for 29 Cases with Recurrent Rectal Cancer.

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Three Dimensional-Conformal Radiotherapy Combined with Capecitabine Chemotherapy for Locally Advanced Rectal Cancer

Pre-operative radiochemotherapy of locally advanced rectal cancer.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Tumor pathological response and downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: comparison of two radiation dose schedules

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Management of Locally Advanced Rectal Cancer with Preoperative Three-Dimensional Conformal Radiotherapy Combined with Chemotherapy

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Postoperative Capecitabine With Concurrent Intensity-Modulated Radiotherapy Or Three-Dimensional Conformal Radiotherapy For Patients With Stage Ii And Iii Rectal Cancer

Concurrent Three Dimensional Conformal Radiotherapy and Chemotherapy with DF Regime in the Treatment for 33 Cases with Advanced Esophageal Carcinoma

Three Dimensional-Conformal Radiotherapy Combined with Gemcitabine Chemotherapy for Locally Advanced Pancreatic Cancers

Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial.

Phase Ii Study of Irinotecan and Capecitabine Concurrent with Intensity Modulated Radiation Therapy in the Treatment of Recurrent Rectal Cancer

Three dimensional-conformal radiotherapy combined with gemcitabine chemotherapy for locally advanced non-small cell lung cancer

The Preliminary Study of the Conformal Radiation Therapy for 7 Patients with Prostate Carcinoma

Outcome of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy for inoperable locally advanced pancreatic cancer